Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
However, in the pivotal Phase IIb trial, it failed to demonstrate statistically significant weight loss compared to placebo at the primary endpoint, leading the developer (Metabolic Pharmaceuticals Ltd.) to terminate the commercial program
Fasti Arvales ad 1
Also, advise of any health or medication changes
Anti-Inflammatory and Antioxidant Effects GHK-Cu demonstrates potential anti-inflammatory and antioxidant effects
Longevity & aging Investigated in preclinical research on cellular aging, sirtuin activity, and the age-related decline of NAD+ levels
US$ 23.79
US$ 21.26
US$ 20.46
US$ 29.78
US$ 23.97
US$ 22.96
US$ 20.61
